Next report date
Report period
Q1 2024
EPS estimate
−0.40USD
Revenue estimate
950.00 KUSD
−1.48USD
−49.12 MUSD
2.76 MUSD
22.22 M
About Orchestra BioMed Holdings, Inc.
Sector
Industry
CEO
David P. Hochman
Website
Headquarters
New Hope
Employees (FY)
56
Founded
2020
FIGI
BBG00W5FR2T5
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded on May 25, 2020 and is headquartered in New Hope, PA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of OBIO is 4.44 USD — it has decreased by 0.89% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Orchestra BioMed Holdings, Inc. stocks are traded under the ticker OBIO.
Orchestra BioMed Holdings, Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
OBIO stock is 8.29% volatile and has beta coefficient of 1.07. Check out the list of the most volatile stocks — is Orchestra BioMed Holdings, Inc. there?
OBIO earnings for the last quarter are −0.38 USD per share, whereas the estimation was −0.39 USD resulting in a 2.56% surprise. The estimated earnings for the next quarter are −0.38 USD per share. See more details about Orchestra BioMed Holdings, Inc. earnings.
Orchestra BioMed Holdings, Inc. revenue for the last quarter amounts to 419.00 K USD despite the estimated figure of 895.00 K USD. In the next quarter revenue is expected to reach 994.50 K USD.
Yes, you can track Orchestra BioMed Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
OBIO stock has fallen by 5.73% compared to the previous week, the month change is a 17.32% fall, over the last year Orchestra BioMed Holdings, Inc. has showed a 70.34% decrease.
OBIO net income for the last quarter is −12.82 M USD, while the quarter before that showed −13.32 M USD of net income which accounts for 3.74% change. Track more Orchestra BioMed Holdings, Inc. financial stats to get the full picture.
Today Orchestra BioMed Holdings, Inc. has the market capitalization of 160.28 M, it has decreased by 3.43% over the last week.
No, OBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, OBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Orchestra BioMed Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 56.00 employees. See our rating of the largest employees — is Orchestra BioMed Holdings, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Orchestra BioMed Holdings, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Orchestra BioMed Holdings, Inc. stock shows the sell signal. See more of Orchestra BioMed Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Orchestra BioMed Holdings, Inc. future price: according to them, OBIO price has a max estimate of 20.00 USD and a min estimate of 14.00 USD. Read a more detailed Orchestra BioMed Holdings, Inc. forecast: see what analysts think of Orchestra BioMed Holdings, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Orchestra BioMed Holdings, Inc. EBITDA is −50.91 M USD, and current EBITDA margin is −1.86 K%. See more stats in Orchestra BioMed Holdings, Inc. financial statements.